P1‐103: Use of medications with clinically important drug‐drug interactions (DDIS) with direct‐acting antivirals (DAAS) for the treatment of chronic hepatitis C (CHC) infection: focus on ethinyl estradiol and HMG‐CoA reductase inhibitors

首页> 外文期刊>Journal of viral hepatitis. >P1‐103: Use of medications with clinically important drug‐drug interactions (DDIS) with direct‐acting antivirals (DAAS) for the treatment of chronic hepatitis C (CHC) infection: focus on ethinyl estradiol and HMG‐CoA reductase inhibitors

【24h】

P1‐103: Use of medications with clinically important drug‐drug interactions (DDIS) with direct‐acting antivirals (DAAS) for the treatment of chronic hepatitis C (CHC) infection: focus on ethinyl estradiol and HMG‐CoA reductase inhibitors

机译：P1-103：使用临床上重要的药物 - 药物相互作用（DDIS）用直接作用抗病毒（DAAS）用于治疗慢性丙型肝炎（CHC）感染的药物：焦点对乙基雌二醇和HMG-COA还原酶抑制剂

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Journal of viral hepatitis.》 |2018年第s1期|共1页
作者

展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类传染病;
关键词

相似文献

外文文献
中文文献
专利

1. P1‐103: Use of medications with clinically important drug‐drug interactions (DDIS) with direct‐acting antivirals (DAAS) for the treatment of chronic hepatitis C (CHC) infection: focus on ethinyl estradiol and HMG‐CoA reductase inhibitors [J] . Journal of viral hepatitis. . 2018,第S1期

机译：P1-103：使用临床上重要的药物 - 药物相互作用（DDIS）用直接作用抗病毒（DAAS）用于治疗慢性丙型肝炎（CHC）感染的药物：焦点对乙基雌二醇和HMG-COA还原酶抑制剂
2. The efficacy and safety of direct acting antiviral treatment and clinical significance of drug-drug interactions in elderly patients with chronic hepatitis C virus infection [J] . Vermehren J., Peiffer K. -H., Welsch C., Alimentary pharmacology & therapeutics. . 2016,第8期

机译：直接作用抗病毒治疗在老年慢性丙型肝炎病毒感染患者中的疗效和安全性以及药物相互作用的临床意义
3. Changes in the use of direct acting antiviral(s) (DAA) in the treatment of chronic hepatitis C (CHC) patients in clinical practice. HERACLIS: a Hellenic multicenter real-life cohort clinical study [J] . Papatheodoridis George V., Koskinas John, Goulis Ioannis, Hepatology: Official Journal of the American Association for the Study of Liver Diseases . 2017,第Suppla1期

机译：直接作用抗病毒（DAA）在临床实践中治疗慢性丙型肝炎患者的使用变化。 Heraclis：Hellenic MultiCenter现实生活队列临床研究
4. Analyzing the Impact of the CMS Guidance on Assuring Access to Hepatitis C Virus (HCV) Drugs on Utilization of Direct-Acting Antiviral (DAA) Agents [D] . Ferrell, Kelli Walker. 2017

机译：分析CMS指南对确保获得丙型肝炎病毒（HCV）药物对直接作用抗病毒（DAA）药物利用的影响
5. P-022. Prevalence of the potential drug-drug interactions between pangenotypic direct-acting antivirals and the concomitant medication with patients with chronic hepatitis C virus infection [O] . Antoni Sicras Mainar, Sabahattin Kaymakoglu 2019

机译：P-022。全基因型直接作用抗病毒药与慢性丙型肝炎病毒感染患者同时用药之间潜在药物相互作用的发生率
6. The efficacy and safety of direct acting antiviral treatment and clinical significance of drug-drug interactions in elderly patients with chronic hepatitis C virus infection [O] . J. Vermehren, K.-H. Peiffer, C. Welsch, 2016

机译：老年慢性丙型肝炎病毒感染患者药物 - 药物 - 药物 - C病毒感染患者直接作用抗病毒治疗及临床意义的疗效和安全性
7. Guidance for Industry Chronic Hepatitis C Virus Infection: Developing Direct-Acting Antiviral Agents for Treatment [R] . 2010

机译：工业慢性丙型肝炎病毒感染指南：开发直接作用的抗病毒药物进行治疗

P1‐103: Use of medications with clinically important drug‐drug interactions (DDIS) with direct‐acting antivirals (DAAS) for the treatment of chronic hepatitis C (CHC) infection: focus on ethinyl estradiol and HMG‐CoA reductase inhibitors

著录项

相似文献

相关主题

期刊订阅